Frank G. Holz

Aug 26, 2024 | nature.com | Ashish Sharma |Peter Kaiser |Frank G. Holz |Sobha Sivaprasad |Taku Wakabayashi |Nilesh Kumar | +3 more

The majority (95.2%) of the ophthalmologists were aware of all the ranibizumab biosimilars available in India. Biosimilar ranibizumab was the most common ranibizumab administered with 50–100% usage in 51% respondents whereas the proportion of originator usage was below 25% in the majority of practices (62.8%) (Fig. 1B).

Sep 8, 2023 | eyetube.net | Ramin Tadayoni |Frank G. Holz

Biosimilars in Retina Ramin Tadayoni, MD, PhD, and Prof. Frank Holz Show Description + As we enter the era of biosimilars in retina, Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, invites Prof. Frank Holz to update viewers on the state of biosimilars in retina. They discuss what biosimilars are, how they are approved, whether they might offer cost savings to health care systems, and which markets might be best suited for rapid biosimilar adoption.